Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Sudarshan Pharma Industries Ltd (543828)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543828 NSE: Pharmaceuticals & Drugs | Small Cap | Sudarshan Pharma (I) Share Price
₹39.30 -0.56 (-1.40%)
As on 23-Sep'26 11:01
Sudarshan Pharma Industries Ltd (543828)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543828 NSE: Pharmaceuticals & Drugs | Small Cap | Sudarshan Pharma (I) Share Price
₹39.30 -0.56 (-1.40%)
As on 23-Sep'26 11:01
Key Metrics
Valuation Multiples
Market Cap
₹1,014 Cr.
Current Price
₹39.3
52-Week Low / High
₹19 / 43
TTM EPS
₹1
TTM Sales
₹732 Cr.
Book Value per Share
₹12.9
P/E Ratio
40.38
Higher than its 5-year historical median
Industry PE
54.8
Price to Book (P/B)
3.09
Lower than its 5-year historical median
Price to Sales (P/S)
1.39
Higher than its 5-year historical median
EV/EBITDA
19.98
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
13.33%
Return on Capital Employed (ROCE)
14.42%
Return on Assets (ROA)
4.65%
Operating Profit Margin
7.9%
Net Profit Margin
3.16%
Gross Profit Margin
5.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
7.94%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
75.01%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
39.18%
Asset Quality
Promoter Holding
58.93%
Pledged shares (%) of Promoter's holding (%)
1.36%
Reserves
₹303 Cr.
Equity
₹25.5 Cr.
Face Value
₹1
All Time Low / High
₹5.18 / 53.50
Check Before You Invest
Quality
Somewhat GoodValuation
FairCheck Valuation charts
Price Trend
Weak
Is Sudarshan Pharma Industries Ltd a good quality company?
Sudarshan Pharma Industries Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Sudarshan Pharma Industries Ltd performance compare with that of its Peers?
Revenue growth of Sudarshan Pharma Industries Ltd vs industry peers?
Sudarshan Pharma Industries Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Sudarshan Pharma Industries Ltd?
Promoters hold 58.93% of the Sudarshan Pharma Industries Ltd, with 1.36% of their stake pledged, indicating low pledge risk.
Stock return of Sudarshan Pharma Industries Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 66.53% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sudarshan Pharma Industries Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 16% | 12.2% | 16% | 19.5% | 12% | 14.6% | 18.7% | 15.3% | 13.7% | 14.3% | - |
| Value Creation Index ⓘ | 0.1 | -0.1 | 0.1 | 0.4 | -0.1 | 0.1 | 0.3 | 0.1 | 0.0 | 0.0 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 37.9 | 55.4 | 88.2 | 139 | 148 | 193 | 357 | 461 | 466 | 503 | 691 |
| Sales YoY Gr. | - | 46.1% | 59.2% | 57.8% | 6.4% | 30.7% | 84.7% | 29.2% | 0.9% | 7.9% | - |
| Adj EPS ⓘ | 0.3 | 0 | 0.1 | 0.3 | 0.1 | 0.3 | 0.6 | 0.3 | 0.5 | 0.8 | 1 |
| YoY Gr. | - | -88.2% | 125% | 177.8% | -44% | 92.9% | 103.7% | -45.5% | 56.7% | 59.6% | - |
| BVPS (₹) ⓘ | 0.6 | 0.9 | 1.1 | 2 | 2.1 | 2.4 | 3.1 | 4.2 | 4.6 | 5.3 | 12.8 |
| Adj Net Profit ⓘ | 0.1 | 0.2 | 0.7 | 2.3 | 1.3 | 2.6 | 5.3 | 7.2 | 11.2 | 18 | 24 |
| Cash Flow from Ops. ⓘ | 1.8 | -1.6 | -0 | -1 | 0.5 | 2.7 | -3.7 | -28.8 | 9.7 | 34.9 | - |
| Debt/CF from Ops. ⓘ | 1.2 | -3.6 | -1286.2 | -14.3 | 40.4 | 11.1 | -8.3 | -1.2 | 11 | 5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 33.3% | 27.7% | 12.1% | 7.9% | ||||
| Adj EPS ⓘ | 9.2% | 39.9% | 10.9% | 59.6% | ||||
| BVPSⓘ | 27.2% | 20.6% | 20.2% | 14.2% | ||||
| Share Price | - | - | 66.5% | 39.9% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 56.1 | 9.3 | 12.6 | 17.2 | 6.9 | 12.3 | 20.3 | 11 | 10.6 | 14.8 | 10.5 |
| Op. Profit Mgn % ⓘ | 0.9 | 1.1 | 0.8 | 3.1 | 3.3 | 3.7 | 3.1 | 3.2 | 4.9 | 7.7 | 8 |
| Net Profit Mgn % ⓘ | 0.2 | 0.3 | 0.8 | 1.7 | 0.9 | 1.3 | 1.5 | 1.6 | 2.4 | 3.6 | 3.5 |
| Debt to Equity ⓘ | 12.9 | 1.8 | 1.2 | 0.8 | 1.1 | 1.3 | 1 | 0.3 | 1 | 1.4 | - |
| Working Cap Days ⓘ | 0 | 88 | 102 | 96 | 116 | 135 | 113 | 126 | 170 | 213 | 102 |
| Cash Conv. Cycle ⓘ | 0 | 28 | 40 | 42 | 61 | 65 | 46 | 45 | 81 | 130 | 12 |
Valuation of Sudarshan Pharma (I) - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|
| Sales | 193 | 357 | 461 | 464 | 505 |
| Operating Expenses ⓘ + | 186 | 346 | 447 | 441 | 465 |
| Operating Profit ⓘ | 7 | 11 | 15 | 23 | 40 |
| Operating Profit Margin (%) | 3.7% | 3.1% | 3.2% | 4.9% | 7.9% |
| Other Income ⓘ + | 0 | 0 | 1 | 3 | 3 |
| Interest ⓘ | 3 | 3 | 5 | 9 | 16 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 2 |
| Profit Before Tax ⓘ | 4 | 7 | 9 | 15 | 22 |
| Tax ⓘ | 1 | 2 | 2 | 4 | 6 |
| Profit After Tax | 3 | 5 | 7 | 11 | 16 |
| PAT Margin (%) | 1.4% | 1.5% | 1.5% | 2.5% | 3.2% |
| Adjusted EPS (₹) | 0.3 | 0.5 | 0.3 | 0.5 | 0.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 10.30% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 23 | 30 | 101 | 112 | 128 | ||||||
| Debt + | 27 | 29 | 31 | 101 | 167 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | ||||||
| Trade Payables | 44 | 74 | 92 | 57 | 92 | ||||||
| Others Liabilities ⓘ | 6 | 5 | 8 | 14 | 16 | ||||||
| Total Liabilities ⓘ | 99 | 138 | 232 | 283 | 402 | ||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 6 | 6 | 20 | 26 | 24 | ||||||
| CWIP ⓘ | 0 | 1 | 0 | 2 | 6 | ||||||
| Investments ⓘ | 0 | 0 | 12 | 14 | 30 | ||||||
| Inventories | 24 | 47 | 75 | 86 | 140 | ||||||
| Trade Receivables | 60 | 73 | 82 | 123 | 160 | ||||||
| Cash Equivalents | 1 | 0 | 12 | 0 | 1 | ||||||
| Others Assets ⓘ | 7 | 10 | 32 | 33 | 41 | ||||||
| Total Assets ⓘ | 99 | 138 | 232 | 283 | 402 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 3 | -4 | -29 | 8 | 35 |
| Cash Flow From Investing Activity ⓘ + | -1 | -1 | -26 | -7 | -20 |
| Cash Flow From Financing Activity ⓘ + | -1 | 4 | 66 | -12 | -14 |
| Net Cash Flow ⓘ | -0 | -1 | 11 | -12 | 0 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 11.87 | 20.08 | 10.76 | 10.77 | 13.33 | |||||
| ROCE (%) | 13.01 | 18.67 | 15.25 | 13.75 | 14.42 | |||||
| Asset Turnover Ratio | 1.95 | 3.02 | 2.49 | 1.8 | 1.47 | |||||
| PAT to CFO Conversion(x) | 1 | -0.8 | -4.14 | 0.73 | 2.19 | |||||
| Working Capital Days | ||||||||||
| Receivable Days | 114 | 68.40 | 61.30 | 80.30 | 102.20 | |||||
| Inventory Days | 45.20 | 36.20 | 48 | 63.10 | 81.80 | |||||
| Payable Days | 90.90 | 64.30 | 70.20 | 64.10 | 62.10 | |||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Sudarshan Pharma Industries Ltd FAQs
The current trading price of Sudarshan Pharma (I) on 23-Sep-2026 11:01 is ₹39.30.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Sudarshan Pharma (I) stood at ₹1,014.3 Cr
The latest P/E ratio of Sudarshan Pharma (I) as of 22-Sep-2026 is 41.76.
The latest P/B ratio of Sudarshan Pharma (I) as of 22-Sep-2026 is 3.11.
The 52-week high of Sudarshan Pharma (I) is ₹42.79 and the 52-week low is ₹18.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sudarshan Pharma (I) is ₹691 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sudarshan Pharma Industries Ltd is a average quality company.
The key valuation ratios of Sudarshan Pharma Industries Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sudarshan Pharma Industries Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries was originally incorporated on July 23, 2008 as a Private Limited Company as “Sudarshan Speciality Chemsolve Private Limited” under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from “Sudarshan Specialty Chemsolve Private Limited” to “Sudarshan Pharma Industries Private Limited” under the Companies Act, 2013 pursuant to a special resolution passed by its shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of its Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016 the company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the company was changed to ‘Sudarshan Pharma Industries Limited’ and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai.
The company is engaged in the business of manufacturing and trading of specialty chemicals & intermediates for pharma, agro chemicals, coating, paints, adhesive and various other industries. It is also into Active Pharmaceuticals Ingredients manufacturing. Some products it outsources and manufactures at its toll manufacturing facility, it is also into specialty chemicals imports & exports as well as supply of same to the actual users. As per the clients need and requirements, it provides customize specialty chemicals to its clients in India and abroad regularly. Its Specialty chemicals & its Intermediates have wide application in sectors like pharma, agro chemicals, performance chemicals, resins, paint, food, adhesive and various other Industries.
It is also involved in contract manufacturing, outsource & supply of generic pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals. It carries about Ethical marketing of pharmaceutical formulation & products in the Domestic and International market through its own distribution network and Sales force under its own brands. The company & its executives have developed the skill and expertise in innovation in specialty chemical, bulk drugs, API and pharmaceutical formulation to provide the products having wide application in pharma, agro chemicals, performance chemicals, resins, paint, food, adhesive and various other Industries. It offers services of QC and Formulation Development to provide customised solutions to its customers and assists them in sourcing the innovative products as per their needs.
Business area of the company
The company is engaged in the business of manufacturing and trading of Specialty Chemicals, Intermediates & Active Pharmaceuticals Ingredients.
Products and services of the company
- Pharmaceuticals, finished formulations, key starting materials for API
- Bulk drugs and intermediates
- Paints, coatings, corrosive, inhibitors & inks
- Food, fragrance & perfumes
- Pesticides and agro chemicals
- Fiber, PVC and adhesives
- Cosmetic and detergents
History and milestones
- 2008: Incorporation of the company in the name and style of “Sudarshan Specialty Chemsolve Private Limited”
- 2011: Generic formulations for institution supply, NGO’s and wholesale market
- 2012: Branded Generic formulations in Maharashtra
- 2013: Established its footprints in Gujarat, West Bengal, Chhattisgarh and Uttar Pradesh
- 2014: Introduced brands in New Drug Delivery System
- 2015: Over 5,000 medical practitioners associated with SPIL
- 2016: Company’s name was changed from “Sudarshan Specialty Chemsolve Private Limited” to “Sudarshan Pharma Industries Private Limited”
- 2016: 7 own branded products introduced successfully in Vimac
- 2017: Conversion of the company from Private Limited Company to Public Limited Company and Change of name of Company to Sudarshan Pharma Industries Limited
- 2018: Brand Brilliance Award from Asian African leadership forum in Pharma
- 2019: Launch Hart Kit Loading Dose and Hart Kit-4
- 2021: VD-Section Got 50.00 crore Government order (Started work on CORONA protection)
You have 44 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
